The non-receptor tyrosine kinase Fer belongs to a distinct subfamily of F-BAR domain containing kinases implicated in vesicular trafficking and signaling downstream of adhesion and growth factor receptors. Targeted inactivation of the fer gene in a transgenic mouse model of HER2 + , breast cancer was associated with delayed tumor onset and reduced proliferative rates in tumor cells. Fer deficiency was associated with increased rates of epidermal growth factor (EGF)-induced epidermal growth factor receptor (EGFR) internalization and amplified Ras-Raf-Mek-Erk (Ras-MAPK) signaling in primary mammary tumor epithelial cells, as well as increased cytotoxic and anti-proliferative sensitivity to the dual EGFR/HER2 inhibitor Lapatinib (LPN). These observations suggest a model in which accelerated ligand-induced EGFR internalization in Fer-deficient cells hypersensitizes the Ras-MAPK pathway to EGF, resulting in MAPK signal amplification to levels that induce cytostasis, rather than proliferation. Thus, Ras-MAPK cytostatic signaling delays HER2 tumor initiation and increases LPN cytotoxicity in Fer-deficient model systems. Taken together, these data suggest that targeting Fer alone, or in combination with LPN, may be of therapeutic benefit in HER2 + breast cancer.
INTRODUCTION
Epidermal growth factor receptor (EGFR)/Her1/ErbB1 signaling has been frequently implicated in the progression of carcinomas. 1 Activation of EGFR by epidermal growth factor (EGF) induces dimerization with and activation of its homologous family member HER2/ErbB2. HER2 is overexpressed in about 30% of primary mammary tumors and has been established as a relevant prognostic biomarker and therapeutic target in breast cancer. 2, 3 EGFR and HER2 are coupled to the Ras-Raf-Mek-Erk (Ras-MAPK) pathway, which has a central role in the development and progression of cancer. 4 Activation of this pathway is detected in 30% of all human cancers and its unregulated activity has been correlated with aberrant cell proliferation and survival. Inhibition of EGFR-Ras-MAPK signaling is a focal point of targeted anticancer strategies.
Investigations of EGFR activation, trafficking and signaling have contributed to a paradigmatic understanding of the mechanisms underlying oncogenic receptor tyrosine kinase signaling. Activated EGFR complexes recruit signal propagating SH2-or PTB-domain containing adapter proteins, which are subsequently internalized by clathrin-dependent (CD) pathways. 1 These complexes continue to signal before they are inactivated in the endosome, recycled to the surface or targeted for lysosomal degradation. 5 EGFR internalized by CD routes is preferentially recycled, and this has been implicated in sustaining Ras-MAPK signaling. 6 A diverse range of extracellular ligands activate the ErbB receptor family by inducing multiple homo-and heterodimer pairings, allowing combinatorial generation of signal redundancy and diversity. 7 Stimulation of EGFR by EGF gives rise to EGFR homodimers, and EGFR-HER2 heterodimers. 8, 9 HER2 itself has no known extracellular ligand and is thought to function as a nonautonomous signal amplifier that potentiates mitogenic and survival signaling elicited by ligand activation of its heterodimeric partners. 7 Mutations in autophosphorylation sites in the cytoplasmic domain of a HER2/NEU oncoprotein encoded by an activated rodent neu transgene (neu NT ) compromised its transforming potential and decreased tumor latency in mice. 10 These antitumor effects were correlated with Ras-dependent Erk and Akt activation in vivo, suggesting that signals from these pathways potentiate HER2 tumorigenesis.
Fer, together with the paralogous Fps/Fes kinase, make up a distinct subclass of cytoplasmic protein tyrosine kinases. Fer is activated by both EGF and platelet-derived growth factor stimulation. 11, 12 Fer directly interacts with both the EGFR and HER2 through its SH2-domain. 13 Fer can also be activated by other cytokines, including erythropoietin and steel factor, and by integrin engagement. [14] [15] [16] These activities have been correlated with multifunctional cellular roles for Fer in adhesion, survival, proliferation and migration; however, the molecular mechanisms by which Fer regulates these functions remain unknown. Fer harbors N-terminal sequences homologous to F-BAR domains. 17, 18 F-BAR domains are implicated in membrane binding and bending events involved in receptor endocytosis and vesicular trafficking. 19, 20 This suggested a potential role for Fer in regulating EGFR signaling through effects on trafficking. We present novel evidence that Fer inhibits the rate of EGFR internalization. In HER2 overexpression model systems, this inhibitory role for Fer effectively buffers Ras-MAPK signaling to optimal mitogenic levels associated with progression of HER2 tumorigenesis, as suggested by delayed HER2 tumor onset in mice lacking Fer kinase activity.
RESULTS

Accelerated EGFR internalization in Fer-deficient mammary tumor epithelial cells correlates with enhanced Ras-MAPK signaling
An F-BAR domain in Fer suggested a possible function for this kinase in regulating receptor internalization. EGF-induced EGFR internalization rates were therefore tested in primary mouse mammary tumor epithelial cells (MTECs) isolated from mouse mammary tumor virus-Neu (neu NT ) transgenic mice with or without a targeted D743R fer mutation, that both abolishes kinase activity and destabilizes the protein (fer DR/DR ) 12 (Supplementary Figure S1A ). EGFR internalization rates were elevated twofold in fer DR/DR MTECs relative to wild type (fer +/+ ) counterparts ( Figure 1a ). Furthermore, the rate of EGF-induced receptor internalization was reduced by twofold in the human HER2 overexpressing breast cancer cell line SKBR3 upon ectopic expression of Fer (Figure 1b, Supplementary Figure S1B ). These data suggest that Fer negatively regulates the rate of EGFR internalization and raises the possibility that Fer regulates the efficiency of CD endocytosis. As the rate of CD endocytosis has been implicated in promoting downstream Ras-MAPK signaling, we next compared short-term EGF-induced effects on Ras-MAPK signaling in neu NT |fer +/+ and neu NT |fer DR/DR MTECs. Erk activity or signal strength, as assessed by a phospho-specific antibody that recognizes the active state of Erk (pErk), was used as a surrogate of Ras-MAPK signal output through this pathway. Remarkably, EGF-induced Mek and Erk signal strengths were enhanced in fer DR/DR MTECs relative to wild-type MTECs (Figures 1c and d, respectively; Supplementary Figure S2A ). Conversely, EGF-induced Erk signaling was suppressed in SKBR3 cells ectopically expressing Fer (Figure 1e ; Supplementary Figure S2B ). We were also interested in how expression of a stable kinase-dead Fer protein (mimicking effective pharmacologic inhibition) would effect EGFinduced EGFR internalization and Ras-MAPK signaling. fer DR/DR MTEC variants expressing Myc epitope tagged wild type or kinasedead Fer (K592R mutation of the conserved ATP binding site; 21 Supplementary Figure S1D ) displayed reduced or enhanced EGFR internalization (Supplementary Figure S1E) ; and this correlated with reduced or enhanced EGF-induced Erk activation, respectively (Supplementary Figure S1F ). These observations suggested that stronger EGF-induced signaling responses in the Fer-deficient MTECs are associated with enhanced EGFR internalization through CD pathways.
Enhanced steady-state Ras-MAPK activity in neu NT |fer DR/DR tumors correlates with reduced proliferative potential and delayed tumor onset Steady-state Ras-MAPK signaling in vivo may be driven by stable EGF input, which could be further potentiated by elevated HER2 expression in tumors. 7, 22, 23 This led us to hypothesize that the transiently observed increases in EGF-induced Ras-MAPK signal strength in fer DR/DR MTECs might reflect enhanced steady-state Mek, n = 4, P = 0.003; Erk, n = 4, P = 0.01; 2-way analysis of variance (ANOVA)). A representative blot is shown in Supplementary Figure S2A . (e) Short-term EGF-induced Erk activation kinetics in SKBR3-vector or SKBR3-FerMyc as assessed by in cellimmunocytochemistry (mean ± s.e.m., P o0.0001; 2-way ANOVA). pErk is expressed as a ratio of Erk intensity values. EGF-induced Erk activation kinetics in SKBR3-FerMyc cells was also observed to be diminished in two independent immunoblotting experiments (Supplementary Figure S2B) . signaling in vivo. Immunohistochemical (IHC) analyses showed that active Erk staining was increased in murine neu NT -driven tumors relative to normal mammary glands (Supplementary Figure S3A ); furthermore, active Erk staining was also apparent in human HER2 + breast tumor tissue (Supplementary Figure S3A ). Semiquantitative estimation of active Erk staining intensity in neu NT |fer +/+ and neu NT |fer DR/DR tumor sections suggested that Ras-MAPK signals were more pronounced in Fer-deficient tumors (Figure 2a ). This was apparent as early as 3 days post tumor detection, and became up to threefold higher by day 28 (Figure 2a ). Immunoblotting analyses of resected tumors confirmed these observations, showing threefold increases in steady-state Erk activity in neu NT |fer DR/DR tumors ( Figure 2b ). Increases in Ras-MAPK signaling have been classically associated with increased proliferation. Unexpectedly, blind clinico-pathological evaluation suggested that mitotic and tumor progression indices were reduced in neu NT | fer DR/DR tumors compared with neu NT |fer +/+ tumors (Supplementary Figure S3B ). Quantification of nuclear proliferating antigen (Ki67) staining intensity confirmed reductions in fer DR/DR tumor proliferation indices for up to 14 days post tumor-onset (Figure 2c ; Supplementary Figure S3B ). Additional experiments ex vivo, showed that fer DR/DR MTECs exhibited reduced proliferative capacity ( Figure 2d ) and reduced sensitivity to EGF-induced mitogenesis relative to fer +/+ MTECs (Figure 2f ); and this was associated with increased (EGF-dependent) steady-state Ras-MAPK activity (Figure 2e ). Compellingly, the latter reductions in proliferative and mitogenic potential correlated with delayed tumor onset in neu NT | fer DR/DR mice (Figure 2g ). Taken together, these data suggest a cell autonomous role for Fer in the development of neu NT tumors that is associated with enhanced EGF-dependent proliferation and suppressed EGF-induced Ras-MAPK signaling.
Fer deficiency is associated with hypersensitive cytotoxic responses to Lapatinib and enhanced Ras-MAPK responses to EGF To gain insight into the link between accelerated EGFR internalization and the anti-tumorigenic effect of Fer deficiency, we compared the relative dependence of fer +/+ and fer DR/DR MTECs on EGFR survival signaling. Pharmacological perturbation with the dual EGFR and HER2 inhibitor Lapatinib (LPN), showed that fer DR/DR MTECs are an order-of-magnitude more sensitive to the cytotoxic effects of LPN than fer +/+ MTECs (Figure 3a) . This difference could be rescued by ectopic expression of Fer in fer DR/DR MTECs (Figure 3a, Supplementary Figure S1C ). We next assessed the effect of LPN on Erk inhibition, which lies downstream of EGFR and HER2 signaling. The EC 50 for cell death induction and Erk inhibition by LPN were nearly an order-ofmagnitude apart in fer +/+ or Fer-rescued fer DR/DR MTECs, but were nearly identical in fer DR/DR MTECs (Figures 3b-d ). This suggests a close link between neutralization of Ras-MAPK survival signaling and LPN-induced cytotoxicity in Fer-deficient MTECs. The nature of this link was further explored by assessing the effect of LPN on EGF-induced Erk activity across a wide range of stimulatory and inhibitory concentrations. Ras-MAPK signal strength induced by a range of EGF inputs was greater in fer DR/DR MTECs relative to fer +/+ MTECs (Figure 4a In contrast, Ras-MAPK signal inhibition by LPN in fer DR/DR MTECs is characterized by steeply graded, all-or-none-like responses at higher EGF concentration ranges ( Figure 4b ). Quantification of the pharmacological responsiveness (n), which defines the steepness of MAPK signal decline in individual drug-response curves, showed that fer DR/DR MTECs are hyper responsive to LPNmediated Erk inhibition at EGF concentrations exceeding 5 ng/ml ( Figure 4f ). The enhanced potency and strength of Ras-MAPK signal induction in fer DR/DR MTECs demonstrates that these cells are hypersensitized to EGF input. Interestingly, this increase in sensitivity is associated with increased LPN responsiveness at elevated EGF concentrations.
Enhanced LPN-mediated cytotoxicity in fer DR/DR MTECs is associated with compromised mitogenic responses and poor Ras-MAPK signal-inhibition durability We further investigated the association between LPN-induced cytotoxicity and Ras-MAPK signaling by sampling pErk activity and cell density over a 72 h course of LPN treatment. Growing fer +/+ and fer DR/DR MTECs were dosed at 24 h intervals with fresh media containing EGF and varying concentrations of LPN ( Figure 5 ; arrows 1-3; Supplementary Figure S4 ). This dosing approach was used to minimize effects associated with drug depletion. 24 fer DR/DR MTEC cell densities declined immediately after the first media change (arrow 1), but this does not appear to be due to LPN, because it is also apparent in the absence of drug (Figure 5b ; Supplementary Figure S4 ). Thereafter, cell densities stabilized until 8 h, after which they displayed a LPN dose-dependent decline until 24 h. In contrast, fer +/+ MTECs were more resilient to the media change and drug challenge, displaying little if any loss of cell density for the first 8 h (Figure 5a; Supplementary Figure S4 ). Cell density decreased in a drug dose-dependent manner from 8 to 24 h, but not to the same extent as seen in fer DR/DR MTECs. Media change at 24 h (arrow 2) correlated with an increase in cell density for both fer +/+ and fer DR/DR cells, even in the presence of LPN. This apparent EGF-induced mitogenic effect was reduced in Figure S5) . Concomitant Ras-MAPK signal monitoring showed that LPN transiently inhibited Ras-MAPK signaling in both lines at the first and second LPN challenges (Figures 5c and d ; arrows 1 and 2); but interestingly, signal recovery was more apparent in the fer DR/DR cells. Indeed, after the 48 h media change, Ras-MAPK signaling in fer DR/DR cells appeared resistant to LPN challenge (Figures 5c and d; arrow 3) . These data suggested that signal-inhibition durability is compromised in fer DR/DR MTECs and that signal strengths recover quickly, often to levels exceeding pre-treatment. Similar phenomenon were observed in the context of inhibition of Akt ( Supplementary  Figures S4 and S6 ). Taken together, these data suggested that enhanced cytotoxic sensitivity to LPN in fer DR/DR MTECs is associated with reduced capacity of these cells to compensate mitogenically for drug-induced cell death, and with decreased durability of Ras-MAPK and PI3K-Akt signal inhibition by LPN.
DISCUSSION
Fer-dependent deceleration of EGFR internalization correlates with suppressed MAPK signaling
We show here that Fer deficiency is associated with enhanced EGF-induced EGFR internalization and increased Ras-MAPK signaling (Figure 1) . Interestingly, while this phenotype is reversed by ectopic expression of wild-type Fer, we observed an enhancement of these effects when a kinase-dead variant of Fer is overexpressed ( Supplementary Figures S1D-F ). This suggests that pharmacologic inhibition of Fer may achieve the same effect in vivo. Current views suggest that MAPK signaling is sustained by internalization of EGFR complexes. Studies have shown that Ras-MAPK signaling is specifically suppressed by perturbations that disrupt CD endocytosis, including clathrin/AP-2 knockdown, dominant-negative dynamin mutants and monodansylcadaverine treatment. 6, 25, 26 This view however, has been recently contested by a report in which disruption of CD endocytosis by conditional dynamin depletion failed to correlate with reduced MAPK stimulation. 27 Although our data support the view that Ras-MAPK signaling is potentiated by EGFR internalization, we have not directly shown that the reduced EGFR internalization rates in Fer-deficient systems involves CD routes. Recent progress has shown that in addition to CD internalization, receptors can also be endocytosed through clathrin-independent routes, which preferentially direct EGFR to degradation through canonical endosomal routes. 28, 29 The EGF concentrations used in our study can elicit both CD and clathrin-independent internalization pathways; 6 thus, the suppression of EGFR routing by Fer through either CD or clathrin-independent pathways may be linked with regulation of MAPK signaling.
Mechanisms underlying inhibition of the rate of EGFR internalization by Fer
It remains unclear where along the endocytic process Fer affects EGFR internalization; however, previous studies suggest that several hypothetical mechanisms are plausible. Fer and its paralogue Fes co-localize with peripheral microtubules and phosphorylate tubulin at sites of microtubule formation. 30, 31 Co-localization was dependent upon F-BAR domains and kinase activity, suggesting that Fer may suppress transport of surface signaling complexes through regulation of microtubuledependent vesicle transport. Other studies suggest that Fer could influence actin dynamics underlying receptor trafficking by phosphorylation of the actin-modeling protein cortactin; 15 or alternatively, indirectly influence cortactin functions via Erk-dependent phosphorylation. 32 Another mechanism may involve Grb2 recruitment to activated EGFR, which promotes clathrin-based EGFR endocytosis. 33, 34 Fer interactions with the Grb2 SH2-domain have been described, and informatics predicted a Grb2 SH2-consensus binding site at Y260 of the Fer F-BAR domain. 35 Fer-Grb2 interactions might compete with Grb2-EGFR interactions, 30 thereby influencing receptor internalization rates. 36 Alternatively, increased Ras-MAPK signal sensitivity to EGF observed in fer DR/DR MTECs (Figure 4e ) may reflect increased receptor recycling, leading to higher receptor signal strengths. Phosphatidic acid was shown to bind a putative FX domain of Fer and potentiate its kinase activity. 37 Localized EGF-induced phospholipase D activation at vesicle necks accelerates EGFR endocytosis and transiently elevates levels of the phospholipase D product phosphatidic acid. 23 As phosphatidic acid generation at this locale is rate limiting for endocytosis, phosphatidic aciddependent activation of Fer may have a regulatory role in this endocytic rate-limiting process. In summary, although the mechanism by which Fer regulates EGFR internalization and downstream signaling remains unclear, there are several potential avenues for future studies to explore this question.
Inhibition of EGFR internalization by Fer is associated with suppressed EGF-induced Ras-MAPK signaling, enhanced proliferation and accelerated tumor onset Our data show that augmented Ras-MAPK signal strength and sensitivity to EGF correlates with impaired EGF-dependent proliferation in fer DR/DR systems. Although counter-intuitive from the general view that MAPK signaling is inherently mitogenic, these results are less paradoxical than they would seem. Numerous early reports showed that EGF and EGFR exhibit biphasic effects on proliferation as threshold-exceeding receptor activity or ligand levels are growth inhibitory. [38] [39] [40] More recent reports continue to support this biphasic behavior showing that excessive growth factor-induced Ras-MAPK signaling can induce hypermitogenic (non-G 0 ) arrest, primarily through induction of cyclin-dependent-kinase inhibitors. 41 Our data suggest that such biphasic responses could reflect alterations in sensitivity to EGF imparted by the internalization signaling circuitry. This in turn, could modulate quantitative features of downstream Ras-MAPK signaling implicated in cell response specificity (that is, proliferation, quiescence or differentiation). 42, 43 Thus, EGF input buffering by the internalization machinery could have a role in setting the upper and lower bounds of Ras-MAPK signal strengths appropriate for normal cell proliferation. However, in malignancy, EGFR may be exposed to high levels of EGF, making the system prone to stimulation beyond upper proliferative-response thresholds; 44 and this could be exacerbated by neu NT /HER2 overexpression. Fer may buffer the response of the system to EGF and promote HER2 tumorigenesis by reducing otherwise cytostatic Ras-MAPK signal strengths to levels conducive for proliferation (Supplementary Figure S7B ). We propose that such a mechanism may underlie the pro-tumorigenic effect of Fer observed in neu NT mice (Figure 6 ; Supplementary Figure S7B ). Indeed, meta-analysis of transcriptome data predicts that elevated Fer expression is associated with decreased survival in HER2 breast cancer 45 (Supplementary Figure S8 ). Hence, Fer may mediate oncogenic effects by Figure S5 ). MTECs used in these experiments are those shown in Supplementary Figure S1C. conferring a pro-proliferation fitness benefit under conditions of elevated (cytostatic) EGFR-HER2-Ras-MAPK signaling. Recently, it was shown that cytostatic Ras-MAPK signal strengths conferred an anti-proliferative fitness deficit to vemurafenib-resistant BRafV600E melanomas, which could be turned into a proproliferative fitness benefit through vemurafenib-mediated reduction of Ras-MAPK to optimal proliferation ranges. 46 This highlights the importance of Ras-MAPK signal quantity in proliferative responses, and supports a model in which Fer inhibitors could induce cytostatic Ras-MAPK signal strengths through promoting receptor internalization (Supplementary Figure S7B) .
Fer inhibition could promote the cytotoxic effects of LPN Increased sensitivity to LPN-induced cytotoxicity in fer DR/DR MTECs closely correlated with Ras-MAPK signal neutralization ( Figure 3) ; and increases in cell density in response to periodic challenges with EGF and LPN were more pronounced in fer +/+ MTECs than in fer DR/DR MTECs (Figures 5a and b) . These data suggest that EGF induces proliferative bursts in fer +/+ MTECs with greater efficiency than in fer DR/DR MTECs; further supporting a role for Fer in fine-tuning the proliferative response. This is consistent with observations of hypo-proliferative steady-state tumor cell indices (Figures 2c and d) , enhanced Ras-MAPK signal strength and sensitivity to EGF (Figures 4d and e; Supplementary Figure S7A ), and reduced mitogenicity in Fer-deficient systems (Figure 2f ).
Thus, enhanced LPN cytotoxicity in fer DR/DR MTECs may be caused by inefficient proliferative compensation for cell death as a result of amplified Ras-MAPK signaling states. We propose that Fer inhibition could antagonize this resistance mechanism by inducing cytostatic effects in these populations through hyperinduction of Ras-MAPK signaling.
MATERIALS AND METHODS Reagents
Antibodies against phospho(p)S217/pS221 Mek1/2 (pMek), pT202/pY204 Erk1/2 (pErk), Mek and Erk were obtained from Cell Signaling Technologies (Danvers, MA, USA). Tubulin and Ki67 (clone K-2) antibodies were purchased from Sigma-Aldrich (Oakville, ON, Canada) and Ventana (Tuscon, AZ, USA), respectively. Biotin-EGF and EGF were obtained from Invitrogen (Carlsbad, CA, USA) and R&D systems (Minneapolis, MN, USA), respectively. LPN was purchased from Toronto Research Chemicals (North York, ON, Canada). Fluorescein isothiocyanate-Mouse anti-Bromodeoxyuridine (Brdu) staining kit was obtained from Bd Pharmingen (San Diego, Ca, Usa).
Mice
Mice targeted with a knock-in kinase-inactivating mutation at the fer locus (fer DR/DR mice) were previously reported. 12 Briefly, the targeted germline missense mutation in fer results in a D743R substitution that both eliminates Fer kinase activity and destabilizes the protein, resulting in a null-like phenotype in fer DR/DR mice. neu NT transgenic mice (strain TG.NK), expressing the activated rat neu oncogenic Her2 allele in mammary epithelial cells under the control of the mouse mammary tumor virus long terminal repeat, were obtained from Jackson Labs. neu NT female mice develop mammary tumors with 100% penetrance. 47 Female progeny hemizygous for the neu NT transgene were derived from fer +/DR x neu NT ; fer +/DR crosses and palpated to detect nascent tumors twice a week. 48 Mice were housed at the Animal Care Facility at Queen's University.
Cell lines
MTECs were isolated from tumor bearing neu NT |fer DR/DR and neu NT |fer +/+ mice as described, 49 and cultured in improved minimum essential medium supplemented with 2% fetal bovine serum, 15 ng/ml of EGF, 10 μg/ml insulin, 1 μg/ml hydrocortisone and 20 nM estrogen (Sigma-Aldrich). SKBR3 cells were obtained from ATCC (Manassas, VA, USA) and cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum.
EGFR internalization
The rate of EGF-induced EGFR internalization was estimated using biotin-EGF as a surrogate marker of receptor internalization kinetics in fer +/+ and fer DR/DR MTECs. The procedure has been described previously and was adopted for biotin-EGF-based microtitre assays. [50] [51] [52] Briefly, cells were serum starved for 12-16 h and pulsed with 100 ng/ml biotin-EGF for 0-10 min at 37°C in serum-free medium in the presence or absence of 100-fold molar excess unlabeled EGF. EGFR internalization was assessed by tracking surface and internalized levels of biotin-EGF over time using immunocytochemistry. 53 Surface biotin-EGF levels were assessed in a parallel set of experiments by fixing cells in 3% paraformaldehyde, 0.25% glutaraldehyde for 30 min at 37°C. Internalized biotin-EGF was assessed by acid-stripping receptor-bound EGF followed by membrane permeabilization and fixation. Surface and internalized biotin-EGF were measured chromogenically at 450 nm with a streptavidin-peroxidase conjugate in a Spectramax M5e spectrophotometer (Molecular Devices, Sunnyvale, CA, USA). EGFR internalization rates were estimated from the slope of a straight line fitted to data representing changes in the ratios of internalized to surface EGF over time. 52 At high biotin-EGF concentrations (20-100 ng/ml) approximately 60% of EGFR is internalized by CD and 40% by clathrinindependent. 6 
Ras-MAPK signaling
Ras-MAPK signal activation profiles were assessed by serum starving cells for 12-16 h prior to stimulation with 50 ng/ml EGF for 0-60 min. Cells were lysed in radio-immunoprecipitation assay buffer and Mek and Erk activity were assayed by immunoblotting or pErk was assayed using in-cell immunocytochemistry. For short-term drug-signal interaction experiments, Figure 6 . Fer-dependent inhibition of EGFR internalization promotes HER2 tumorigenesis by minimizing rate-limiting cytostasis induced by amplified Ras-MAPK signaling. We propose that internalization serves to maintain physiologically appropriate dynamical and quantitative relationships between input stimulus and Ras-MAPK signal output. Internalization rates specifically influence the coupling strength between ligand input and signal output. Fermediated inhibition of internalization decreases this coupling strength by buffering Ras-MAPK responses to EGF input. Input buffering could protect against overstimulation and down modulate Ras-MAPK signal strength to levels optimal for eliciting appropriate proliferation during physiological homeostasis. This same buffering effect may promote tumor development by tempering EGF/HER2driven increases in Ras-MAPK signaling that would otherwise be cytostatic.
cells were pretreated with varying concentrations of LPN (0-20 μM) for 30 min prior to treatment with varying concentrations of EGF (0-100 ng/ml) for 5 min. Erk activity was assessed by in cell immunocytochemistry using anti-pErk antibodies as a surrogate measure for Ras-MAPK signal output. For long-term drug-signal interaction experiments, MTECs were cultured under standard conditions in 96-well plates, and treated with constant EGF (50 ng/ml) and varying LPN (0-100 μM) every 24 h. Cell density, Erk and Akt activity were assessed at the indicated times by crystal violet staining and in cell immunocytochemistry, respectively.
Immunohistochemical and biochemical analysis
Tumors were resected at 3, 14 or 28 days post onset from fer +/+ and fer DR/DR mice and embedded in paraffin for IHC (3, 14 and 28 days) or frozen in liquid nitrogen for biochemical studies (14 days). Freshly sectioned paraffin-embedded samples were immunostained for Ki67 antigen or active Erk using the Ventana Discovery XT automated system. Ki67 and pErk staining intensities were estimated using the Aperio Image Analysis Software (Vista, CA, USA). Tumor and tissues were homogenized in radio-immunoprecipitation assay buffer and assayed by western blotting with pErk and Erk antibodies. B and intensities were quantified using ImageJ software (NIH, Bethesda, MD, USA).
Proliferation and cytotoxicity assays
For proliferation experiments, fer +/+ and fer DR/DR MTECs were plated at low density in 6-well (150 000-225 000 cells per well) or 96-well plates (5000-7500 cells per well) and allowed to grow for 24-48 h. For EGFinduced DNA-synthesis experiments, serum-starved cells were pretreated with BrdU and stimulated with increasing concentrations of EGF for 24 h. Fluorescent intensity was detected with an anti-Fluorescein isothiocyanate-BrdU antibody. For cytotoxicity assays, fer +/+ and fer DR/DR MTECs cell were plated at high density in 96-well plates (20 000-25 000 cells per well) in the presence of varying concentrations of LPN for 72 h. Cell viability was assessed by tetrazolium salt reduction (Cell Counting Kit-8; Dojindo Technologies, MD, USA).
Statistics EC 50 and drug responsiveness (n) were estimated by non-linear regression analyses to four parameter sigmoidal functions. Total Ras-MAPK signal strength was estimated as the total area under dose-response curves. Analysis of variances and t-tests were determined using EXCEL (Microsoft Inc., Seattle, WA, USA) and PRISM (GraphPad Software, La Jolla, CA, USA).
